News
Public · Published
Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis
Merck announced positive results from a Phase 2b trial of efinopegdutide, an investigational once-weekly injectable, in adults with biopsy-confirmed MASH and stage F2 or F3 liver fibrosis. The study compared three doses with placebo and an active semaglutide reference arm; the findings were presented at The Liver Meeting and published in The Lancet.
Published:
Updated:
What happened
Merck announced positive results from a Phase 2b trial of efinopegdutide, an investigational once-weekly injectable, in adults with biopsy-confirmed MASH and stage F2 or F3 liver fibrosis. The study compared three doses with placebo and an active semaglutide reference arm; the findings were presented at The Liver Meeting and published in The Lancet.
Confirmed
Global impact / market context
The results could support further development of efinopegdutide for a serious liver condition, potentially creating a future treatment opportunity for Merck. Any commercial benefit remains uncertain because the article gives no detailed outcome figures, approval status, or evidence that the drug is ready for sale.
Analyst inference
The announcement concerns an investigational medicine, meaning it has not been established here as an approved treatment. Positive trial results can strengthen the case for continued development, but without reported measurements or later-stage evidence, the article does not establish likely revenue, timing, or competitive advantage.
Analyst inference
What to watch
- Look for detailed trial results, including how often patients improved on liver disease measures, because the announcement calls the findings positive but supplies no outcome figures. Analyst inference
- Watch for Merck to report whether it plans further clinical testing; the supplied article describes Phase 2b findings but does not state the next development step. Analyst inference
- Track whether later evidence supports both MASH resolution and fibrosis regression, the disease improvements Merck’s medical chief said the company hopes efinopegdutide can provide. Analyst inference
Evidence
- Original source link unavailable